RXO Price Prediction Next Week
Analysis and Insights
Technical Analysis:
RXO's stock price is currently trading at $19.11 as of 2025-03-24, with a 52-week range of $18.75 to $32.82. The stock has recently crossed below its 200-day moving average, a bearish signal. The RSI is currently at 37.70, indicating the stock is no longer oversold but still in a bearish zone. The MACD is negative, suggesting downward momentum.
Fibonacci Levels:
The Fibonacci levels indicate key support and resistance points. The pivot point is at $18.55, with resistance levels at $19.35 and $20.65. The stock is currently trading near the lower end of these levels, suggesting potential weakness.
News Sentiment:
Recent news indicates RXO's stock fell 13% following its Q4 results, reflecting negative investor sentiment. The broader market is mixed, with the Dow gaining 0.13% while the NASDAQ and S&P 500 fell slightly.
Price Prediction:
Based on the technical indicators and news sentiment, RXO's stock is expected to decline next week. The price target is $17.75, testing the lower Fibonacci support level.
Recommendation:
Sell RXO stock as the technical indicators and news sentiment suggest continued downward pressure.
RXO Similar Chart Price Prediction
The price of RXO is predicted to go up 24.63%, based on the high correlation periods with OESX. The similarity of these two price pattern on the periods is 94.66%.
RXO
OESX
Up: 24.63%Similarity: 94.66%
RXO Revenue Forecast
RXO EPS Forecast
RXO FAQs
What is RXO revenue forecast for next quarter？
What is RXO eps forecast for next quarter？
RXO Analyst's Forecast
Lucas Servera
Truist Securities
Strong Buy
2025-03-13
Price Target
$24
Upside
+31.58%
Truist initiated coverage of RXO Inc. with a Buy rating and $24 price target. The company is positioned to benefit from reduced purchased transportation costs following its acquisition of Coyote, the analyst tells investors in a research note. Truist believes a return to a stable freight market, along with savings and synergies from the Coyote deal can lead to adjusted EBITDA reaching over $500M versus the consensus estimate of $370M in 2027.
J. Bruce Chan
Stifel
Hold
2025-01-23
Price Target
$26 → $27
Upside
+3.09%
Brandon Oglenski
Barclays
Buy
2025-01-17
Price Target
$32 → $30
Upside
+19%
